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REVIEW

The Physiological Action of Picolinic Acid in the Human Brain
R.S. Grant 1,2, S.E. Coggan 1 and G.A. Smythe 2
1
School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney NSW,
2052. 2Australasian Research Institute, Sydney Adventist Hospital, 185 Fox Valley Rd., Wahroonga,
NSW, 2076. 3Bioanalytical Mass Spectrometry Facility (BMSF), UNSW, Sydney, NSW 2052.

Abstract: Picolinic Acid is an endogenous metabolite of L-tryptophan (TRP) that has been reported to possess a wide range
of neuroprotective, immunological, and anti-proliferative affects within the body. However the salient physiological function
of this molecule is yet to be established. The synthesis of picolinic acid as a product of the kynurenine pathway (KP) suggests that, similar to other KP metabolites, picolinic acid may play a role in the pathogenesis of inflammatory disorders
within the CNS and possibly other organs.
In this paper we review the limited body of literature dealing with the physiological actions of picolinic acid in the CNS
and its associated synthesis via the kynurenine pathway in health and disease. Discrepancies and gaps in our current knowledge of picolinic acid are identified highlighting areas of research to promote a more complete understanding of its endogenous function in the brain.

Background

Picolinic Acid (PIC) is a six-member ring structure compound (Fig. 1) that has been detected in a variety
of biological mediums including, cell culture supernatants, blood serum1 cerebrospinal fluid (CSF),2
human milk, pancreatic juice and intestinal homogenates.3
PIC is synthesised from L-tryptophan (TRP) via a sequent side branch of the kynurenine pathway
(KP) involving enzymatic shunting of an aminocarboxysemialdehyde intermediate toward PIC over
non-enzymatic synthesis of the neurotoxin quinolinic acid (QUIN) (Fig. 2). TRP catabolism via the KP
reputedly accounts for greater than 95% of the daily TRP turnover in the CNS.4 While a clear
understanding of the physiological role of various KP metabolites and overall pathway dynamics remains
elusive, at least a portion of TRP is converted to the essential pyridine nucleotide, nicotinamide adenine
dinucleotide (NAD).5,6
Alan Mehler7 was the first to postulate that PIC was a metabolic product of the KP. Having identified
that an enzymatic reaction perturbed the formation of PIC away from the synthesis of QUIN, Mehler
questioned whether; a) PIC was a normal metabolic product of TRP with some physiological function
and b) PIC production had some effect on NAD synthesis. While research has confirmed that PIC is a
metabolite of the KP and knowledge of other aspects of the pathway has grown considerably over recent
years, the salient endogenous function of PIC remains elusive, with its effect on NAD metabolism and
significance in the CNS yet to be determined.
Alterations in KP metabolism have been implicated in the pathophysiology of a variety of CNS inflammatory diseases including; Alzheimer’s disease,8–10 Multiple Sclerosis,11 Parkinson’s,12 Cerebral Malaria,13
Amyotropic lateral sclerosis14 and HIV infection.15 It is therefore reasonable to consider whether changes
in PIC levels also correlate with either cellular or clinical pathology in any of these conditions.
In this review we discuss the potential physiological action of PIC identified by previous studies and
place these findings within the context of both relevance to physiological conditions and associated KP
metabolism. Discrepancies and gaps in our current knowledge of PIC are identified and areas of research
that may promote a more complete understanding of PIC’s endogenous function are suggested.

Physical Properties of PIC

Picolinic acid is a six-membered ring structure and isomer of nicotinic acid, containing five carbon
atoms a nitrogen and a carboxyl group at position 2.
Correspondence: R.S. Grant, School of Medical Sciences, Faculty of Medicine, University of New South
Wales, Sydney NSW, 2052. Tel: +612 93853742; Fax: +612 9487 9626. Email: r.grant@unsw.edu.au
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
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Figure 1. Chemical structures of the isomers Picolinic acid a) and Nicotinic acid b).

A number of synonyms exist for picolinic
acid including, Pyridine-2-carboxylic Acid;
2-Pyridinecarboxylic acid; o-Pyridinecarboxylic
Acid and alpha-Pyridinecarboxylic Acid. As a pure
crystal, PIC has a melting point at ~137 oC and is
soluble in water to 887 g/l. The partial molal
volume of PIC at infinite dilution is 83.8 ml mole,
calculated from the density of its aqueous solutions.
The refractivity at infinite dilultion is 31.9 ml mole.
Picolinic acid exists mainly in the zwitterion form
in solution and displays relatively high viscosities
where a 48% solution has about the same
viscosity as a 38% sucrose solution at the same
temperature.16
The most widely researched physical
characteristic of picolinic acid is its efficient
chelator properties. Chelator activity for PIC was
first reported by Weidel in 1879, where PIC was
shown to efficiently chelate both copper and iron.
Later Suzuki et al17 in 1957 reported its efficient
chelation of a range of metals including Ni, Zn,
Cd, Pb and Cu.
Capitalizing on its chelation properties
PIC-metal complexes are now widely used as a
means of introducing bioactive metals into
biological systems. In particular, as the element
chromium appears to play a role in carbohydrate
and lipid metabolism, dietary supplementation
with chromium picolinate has been advocated in
type 2 diabetes.18 As chromium is not assimilated
particularly well from the diet more effective
absorption is achieved through the ingestion of a
PIC-chromium chelate. Chromium picolinate
[Cr(pic)(3)] supplementation reportedly has
effects on blood glucose and lipid metabolism and
body composition.18 In these formulations PIC is
generally considered the non-active ingredient that
72

helps solubilise the metal through the formation
of the chelate complex.

Biological Synthesis
of Picolinic Acid

TRP can be metabolised through oxidative
degradation via the kynurenine pathway (KP)
to one of three main end products; kynurenic
acid (KYNA), PIC and NAD (Fig. 2). The KP
begins with the oxidative cleavage of the
amino acid tryptophan by either of the two
enzymes indoleamine 2,3-dioxygenase (IDO;
EC 1.13.11.17) or tryptophan 2,3-dioxygenase
a l s o c a l l e d t r y p t o p h a n p y ro l a s e ( T D O ;
EC 1.13.11.11) to produce formylkynurenine
(Fig. 2). Both IDO and TDO are haem-requiring
enzymes and are considered rate limiting for
this pathway.
TDO is found predominantly in mammalian
liver and can be induced by a number of factors
including fasting, glucocorticoids, hydrocortisone, L-tryptophan and nicotinic acid.19,20 In
contrast IDO is found mainly in extrahepatic
tissues including brain, placenta, spleen, lung,
kidney, alimentary tract and epididymis. 20,21
Unlike TDO, IDO does not contain an activating
site for tryptophan analogues22 and is induced
primarily by the proinflammatory cytokine
IFN-γ. IDO also uses the reactive oxygen intermediate (ROI) superoxide as opposed to molecular oxygen as a cofactor.22 TDO also differs
from IDO in regard to substrate specificity.
TDO uses L-tryptophan exclusively as substrate whereas IDO can metabolise both L and
D-tryptophan as well as serotonin and other
related indoleamines.23
International Journal of Tryptophan Research 2009:2
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Figure 2. The kynurenine pathway in the CNS.

In the process of PIC synthesis tryptophan
is catabolised through kynurenine to
3-hydroxyanthranilic acid. This is then further
acted upon by the enzyme 3-hydroxyanthranilic
acid oxygenase (3HAO; EC 1.13.11.6), an
enzyme present in both cytosol and synaptosomal
fractions24 to produce the intermediate 2-amino3-carboxymuconic semialdehyde (Fig. 2).
The rate limiting enzyme for PIC production
amino-ß-carboxymuconate-semialdehydedecarboxylase (ACMSD; EC 4.1.1.45) will
preferentially convert this intermediate to
2-aminomuconic semialdehyde with subsequent
non-enzymatic conversion to picolinic acid.25 Non
enzymatic rearrangement of the intermediate
occurs when ACMSD is saturated with substrate26
allowing the production of quinolinic acid
(QUIN). It has been suggested that under normal
conditions these two pathways control equal
flux.27 ACMSD is therefore a key enzyme directing KP metabolism towards PIC production, and
is expressed at a ratio of 1300 : 30 : 1 in kidney,
liver and brain, respectively.28 Not surprisingly
the activity of ACMSD has been shown to be
International Journal of Tryptophan Research 2009:2

inversely proportional to the amount of NAD
synthesised from tryptophan.25

Physiological Role of KP
Metabolism

In the periphery, the role of the KP appears to be
primarily directed toward the production of NAD,
with other KP metabolites excreted unchanged in
high concentrations in the urine.29 In the CNS,
however, the purpose of KP activation is less clear.
Generation of NAD is integral to brain function
and may be derived de novo from tryptophan.6
However, KP activation potentially occurs in all
brain cell types, including neurons,10 astrocytes,30
infiltrating macrophages,31 dendritic cells32 and
blood brain barrier (BBB) endothelial cells.33
With many kynurenines (the collective term for
KP metabolites) showing neuro-modulatory function in the CNS it is unclear at what point synthesis and release of various kynurenines change
from being part of normal physiological processes
to becoming contributors to pathophysiological
activity.
73
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Quinolinic acid (QUIN) and KYNA are two
neuroactive KP metabolites that have received
considerable attention for their modulation of the
excitatory amino acid N-methyl-D-aspartate
(NMDA) receptor. While QUIN shows neurotoxic
effects by over activation of the NMDA receptor,
KYNA offers neuro-protection by blocking
receptor function via an allosteric glycine site.34
Emphasis has, therefore, been placed upon the
importance of maintaining a balanced ratio between
these two metabolites.
Often overlooked however, is the observation
that PIC also shows antagonistic properties
towards the toxic effects of QUIN via an unknown
mechanism.35,36 PIC’s role in maintaining the
balance between neurotoxic and neuro-protective
KP metabolites requires further investigation.

Experimental Actions of PIC:
In vitro and In vivo

On its own, in experimental systems, PIC is
reported to elicit a number of potential effects
within the body, particularly involving immune
function and antimicrobial activity.
In vitro studies suggest that PIC (at supernatant
concentrations of 1–4 mM) can enhance
macrophage effector functions through the
enhancement of interferon-γ (INFγ) dependant
nitric oxide synthase (NOS) gene expression37,38
and induce expression of the macrophage
inflammatory proteins (MIP)1α and 1β.39 While
the mechanism producing the synergism with
IFN-γ is not known PIC mediated induction of
MIP 1α and β is thought to be through an iron
chelation dependant process.

High PIC concentrations (1–4 mM) have also
been reported to selectively inhibit a variety of
viruses in culture including the Human Immunodeficiency virus (HIV), Herpes Simplex virus
(HSV), and Simian virus (SV) in culture.40,41 PIC
appears to produce its antiviral activity through an
initial cytotoxic action which in turn increases
apoptosis of infected cells and a reduction in viral
replication.41 PIC in combination with IFNγ has
also been shown to inhibit retroviral expression of
the J2 retrovirus,42 again through an unknown
mechanism.
Anti-microbial effects of PIC (2.5–40 mM) have
been observed against Mycobacterium avium
complex (MAC), with significant enhancement of
the antimicrobial action of the drugs clarithromycin,
rifampin and various fluoroquinolones.43,44 It is
suggested that as PA efficiently chelates metal ions,
such as Zn2+ and Fe2+ it is therefore likely that its
antimicrobial activity against MAC organisms is
due to its ability to chelate essential metal ions such
as Fe2+. 43
Some investigators have also observed an effect
of PIC on tumour growth. In vivo studies on mice
inoculated with MBL-2 lymphoma cells showed
that those treated with injections of PIC (100 mg/Kg)
in combination with activated macrophages, had
significant increases in lifespan compared to
control. 45 These effects are arguably due to
macrophage activation mechanisms through IFN-γ
mediated mechanisms as suggested previously.45
Importantly high concentrations of PIC, relative
to physiological levels, were used in all of the
investigations discussed above. Tables 1 and 2
highlight the large discrepancy between PIC
concentrations used experimentally in vitro/in vivo

Table 1. PIC concentrations used experimentally.
Reported physiological effects of PIC
Induces MIP 1 α & β expression

1

Enhances IFN-γ mediated NO production
Anti-tumour activity

1

2

Anti-viral: SV-transformed cells
Anti-viral: HIV infected cells
Anti-viral: J2 retrovirus

1

1

1

Anti-microbial: against MAC
complex

1
1

[PIC] used

Reference

4000 μM

39

4000 μM

37

100 mg/kg

45

1000–3000 μM

40

1500–3000 μM

40

4000 μM

42

2500–20000 μM

43

2500–40000 μM

44

2

Experiment performed using; cell culture, whole animal (mouse).
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Table 2. Endogenous concentrations of PIC.
Reported endogenous PIC locations

[PIC] (μM)

Reference

0.299 +/− 0.034

8

Brain (cortical tissue)

0.100–0.150

8

CSF (no brain injury)

0.017 +/− 0.005

8

Plasma

(Table 1) and reported levels of endogenous PIC
(Table 2). With PIC concentrations in vivo generally
ranging within the low to mid nano (10−9) molar
range the milimolar (10−3) concentrations used in
the above cited studies have generally resulted in
an approximately one million fold difference
between physiological and experimental PIC concentrations. While these studies do indicate
possible therapeutic roles for PIC, the large
discrepancy between endogenous and experimental
PIC levels does raise a question over the relevance
of these observations to the natural physiological
function of PIC.

PIC Concentrations in Diseases
of the CNS

An often useful aid to understanding the
physiological role of an uncharacterised biological molecule is the study of changes in the
endogenous levels of the molecule in health and
disease. Current literature in this area is however
limited to a report by Medana et al.13 showing
raised PIC levels in the CSF of patients with
cerebral malaria and a recent report from our own
group in which no significant difference in PIC
levels were identified between different CNS
disease categories.46 Importantly we have shown
that any attempt at correlating PIC levels in the
CNS may be complicated by an apparent diurnal
fluctuation in CSF PIC levels as discussed later
in this review.
As PIC is part of a more complex pathway, it is
relevant to review how other kynurenines are
affected by disease and under what conditions
altered levels have been observed (for summary
see Table 3).
It has been suggested that altered KP metabolism contributes significantly to the pathophysiology of neurodegenerative and inflammatory
disorders of the CNS.34 Lower levels of KYNA
and the enzymes involved in its production have
been found in the plasma, CSF and erythrocytes of
Parkinson’s and Alzheimer’s disease sufferers.9,47,48
International Journal of Tryptophan Research 2009:2

On the other hand, Huntington’s disease subjects
exhibited elevated cortical QUIN levels in the early
stages of disease onset, suggesting excitotoxicity
as the cause of later neurodegeneration.49
Various viral infections show an up regulation
of the entire KP. HIV infection exhibits increased
levels of both QUIN and TRP in the human brain,50
while in the CSF, QUIN has been further correlated
to worsening brain atrophy.51 Poliovirus infected
macaques showed increases of CSF QUIN, KYNA,
L-kynurenine, kynurenine-3-hydroxylase, and
kynureninase activities, with the magnitude of
increase correlating with the severity of observed
motor deficits.52
In a study of African children suffering
from cerebral malaria elevated PIC and QUIN
concentrations predicted a fatal outcome to the
disease.13 These observations are consistent with
results reported in an animal model using centrally
infected (Plasmodium berghei) mice, where CSF
PIC also increased markedly with malarial
infection.53
While some studies have shown that immune
activation can result in elevated PIC levels37–39 a
recent study by our group failed to find any
correlation between CSF PIC concentrations and
CNS disease states.46 This data was generated from
a population of 241 patients that were suspected
of meningitis as well as other nervous system disorders. Immune activation markers such as white
cell count and C-reactive protein also did not show
any correlation with CSF PIC concentrations.
These results led us to investigate whether other
biological factors may influence the production of
PIC in the CNS.

Biological Factors Influencing PIC
Levels in the CNS

We have recently reported that CSF PIC levels in
the CNS may be influenced by both the age of the
subject and time of sample collection.46 This observation has not been previously reported, although
other studies have noted similar patterns for other
75
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Table 3. Altered Kynurenine pathway metabolites in disease.
CNS disease

Alzheimer’s
Parkinson’s

Reference

Alteration of kynurenines in the CNS
(CSF/brain tissueΨ)
QUIN

KYNA

PIC

nt

nt

n/sΨ

8

nt

Ð

nt

9

nt

Ð

nt

12

Ð

nt

11

Ψ

Multiple sclerosis

Ï

Huntington’s

Ï

nt

nt

49

Cerebral Malaria

Ï

Ï

Ï

13

HIV infection

nt

Ï

nt

52

nt

72

Ψ

Down Syndrome

nt

Ï

Amyotrophic

nt

Ï

nt

73

lateral sclerosis

Ï

nt

nt

14

Ï = Elevated levels compared to control, Ð = decreased levels compared to control.
Abbreviations: nt, not tested, n/s, not significant.

kynurenines. In a population without detectable
neurological disease Kepplinger et al.54 and Heyes
et al.9 observed that CSF KYNA levels significantly
increased with advancing age. Consistent with our
observation, the activity of the PIC producing
enzyme ACMSD has been shown to increase
with age in studies of rat kidney, liver and small
intestine.55 Unfortunately, an investigation of ageassociated changes in ACMSD activity in human
tissue is yet to be reported.
From a sample of subjects with no apparent
CNS disease, we observed that CSF PIC concentrations display a significant diurnal variation
depending on the time of sample collection.46
Importantly, QUIN levels did not show this diurnal
pattern, thus making the observation unique to PIC
alone and suggesting the diurnal variation in
ACMSD activity is most likely caused by substrate
availability. Further, this circadian fluctuation was
not observed in CSF PIC levels from patients with
apparent CNS disease, suggesting that this
temporal rhythm in PIC concentrations can be
significantly perturbed during times of immune
activation.
This observed diurnal fluctuation is remarkably
similar to a serial CSF sampling study of 12 healthy
volunteers by Kennedy and colleagues.56 A significant diurnal pattern in CSF TRP metabolism was
observed, with low TRP levels at near noon, and
a maximum reached at 11 pm—midnight. 56
From this, it was proposed that the peak to trough
availability of TRP as a precursor molecule may
76

be of sufficient magnitude to influence other
metabolite processes, such as melatonin secretion,
which also follows a diurnal cycle.56
With a diurnal fluctuation modelled by variations in TRP levels, it can be proposed that the
availability of TRP in the CSF has a direct affect
on substrate availability for CNS PIC production.
Future studies are required to establish what
conditions affect the baseline diurnal fluctuation
of CSF PIC and what pathophysiological/disease
states may be linked to these changes.

Enzymatic Control of PIC
Production: ACMSD

As the availability of substrate will impact the
synthesis of PIC in the CNS,56 it is relevant to
consider whether the activity of surrounding metabolic enzymes could also influence PIC levels.
ACMSD activity will be influenced by the
availability of its relevant substrate which in turn
is dependant on flux through the KP. The activity
of IDO, the rate limiting enzyme of the KP, (Fig. 2)
is therefore positioned to significantly influence
the synthesis of the PIC precursor.
IDO activity has been shown to be involved in a
variety of physiological processes. IDO activation
can influence maternal tolerance toward the
allogenic fetus57 regulate autoimmune disorders,58
and suppress transplant rejection.59 Inhibitors of
this enzyme are, therefore, currently being
developed for cancer immunotherapy.60
International Journal of Tryptophan Research 2009:2
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While the mechanism through which IDO
displays its immune activity appears to involve
tryptophan concentrations in the microenvironment57
the influence of downstream metabolites such as
PIC on these and other activities has not been
extensively investigated.
As ACMSD substrate required for PIC synthesis
is dependant on IDO activity, any therapeutic
manipulation of IDO will affect the synthesis of
PIC. Understanding the pathophysiological role of
PIC may help prevent potential PIC associated side
effects following IDO inhibition.
The position of ACMSD within the KP
establishes it as the rate limiting enzyme for PIC
synthesis (Fig. 2). Interestingly, a number of
nutritional factors and hormonal effects have been
observed to alter the activity of this enzyme.
High protein diets, the diabetic condition61 and
increased glucocorticoids 62 have all been
demonstrated to increase the activity of ACMSD.
Whereas high levels of dietary polyunsaturated
fatty acids,63 peroxisome-proliferators64 and the
environmental plasticizer contaminants, phthalate
esters65 appear to significantly down-regulate
the activity of this enzyme.
While the physiological rationale for these
changes is not known, high protein diets have
previously been shown to also increase enzymes
associated with energy metabolism.66 Is it possible
that ACMSD/PIC may play a role in the regulation
glucose/energy metabolism? It is relevant to note
that a number of metallopicolinate complexes have
been found with insulinomimetic activity where
the presence of the picolinate significantly enhances
the insulin sensitising activity.67
Importantly most studies in this area have
measured the activity of ACMSD from the
peripheral tissue of animal models. Peripheral
tissue data may or may not correlate substantially
with the centrally located human protein which
apparently has a relatively low level of expression.28
The lack of relevant experimental data relating to
the human CNS highlights the need for future
research in this area.

PIC and the BBB

The measurement of PIC in the CSF is assumed to
reflect endogenous PIC production within the CNS
alone. However it is also possible that CSF levels
may be influenced by transfer of PIC from the
peripheral circulation.
International Journal of Tryptophan Research 2009:2

Chromium picolinate is an established dietary
supplement used to treat conditions of insulin
resistance.18 The ability of this complex to produce
affects within the CNS has been queried.68 Aggett
et al.69 reported that divalent metal complexes of
PIC do not readily pass through lipid bilayers. PIC
itself also has a relatively low partition coefficient
(logP = 0.098a) reflecting its low solubility in a
lipophilic medium. This makes it unlikely that PIC
would pass through the BBB on its own. In addition, Smythe and colleagues8 reported that PIC
plasma levels were at concentrations 3–15 times
higher than those in the brain tissue and CSF
(Table 2). For such a concentration ratio to be
maintained, it is thought that limited flux of PIC
occurs between the CNS and the periphery.
While the above observations indicate that CSF
PIC levels reflect PIC synthesis within the CNS,
other KP metabolites may contribute significantly
to their respective cerebral pools.
In experiments using in situ brain perfusion
techniques on rats, L-kynurenine and 3-hydroxykynurenine were found to be taken up into the brain at
significant rates across the BBB via the large amino
acid transporter.70 Owe-Young and colleagues33
recently found that KP activation occurs in BBB
endothelial cells, and when treated with INFγ,
increased the expression of kynurenine but not
QUIN or PIC. That these metabolites contribute to
PIC production through increased substrate availability has been proposed but never tested.71 It
would be beneficial to our understanding in this
area if future studies examined the concentration of PIC in the CNS under conditions of both
peripheral KP supplementation and peripheral KP
activation.
In summary, there are a number of biological
factors that can potentially affect PIC levels and
synthesis in the CNS including; age and circadian
rhythms and hormonal and nutritional factors.
However the physiological role(s) of PIC within
the CNS is not well understood. Improved understanding may be achieved by characterizing the
changes to cell/organ biochemistry/physiology at
PIC concentrations within acceptable physiological concetrations. In addition, it has not been
established whether there is a link between
PIC concentration and any disease state.
Whether PIC production is as clearly connected to
a

Log P calculated by Advanced Chemical Development log P Batch
version 100 software.
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pathophysiological changes as other kynurenines
such as QUIN and KYNA requires further investigation with careful attention to the confounding
effects of age and diurnal rhythm.
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